Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates DOI Open Access
Mayanka Awasthi,

Anthony Macaluso,

Dawn Myscofski

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 20, 2023

Abstract TNX-1800 is a synthetically derived live chimeric Horsepox Virus (rcHPXV) vaccine expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. vaccination well tolerated, as indicated by lack serious adverse events or significant changes clinical parameters. A single dose generated robust humoral responses African Green Monkeys Cynomolgus Macaques, measured total binding anti-SARS-CoV-2 S IgG neutralizing antibody titers against strain. In induced strong interferon-gamma (IFN-γ) mediated T cell response, promoting both pathogen clearance upper lower airways generation systemic response WA strain Future studies will assess newly emerging variants demonstrate its safety humans.

Language: Английский

Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates DOI Creative Commons
Mayanka Awasthi,

Anthony Macaluso,

Dawn Myscofski

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(11), P. 1682 - 1682

Published: Nov. 2, 2023

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. vaccination well tolerated no serious adverse events or significant changes clinical parameters. A single dose generated humoral responses African Green Monkeys Cynomolgus Macaques, as measured by total binding anti-SARS-CoV-2 S IgG neutralizing antibody titers against strain. In addition, induced an interferon-gamma (IFN-γ)-mediated T-cell response Macaques. Following challenge SARS-CoV-2, Macaques exhibited rapid clearance upper lower respiratory tract. Future studies will assess newly emerging variants demonstrate its safety humans.

Language: Английский

Citations

4
Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates DOI Open Access
Mayanka Awasthi,

Anthony Macaluso,

Dawn Myscofski

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 20, 2023

Abstract TNX-1800 is a synthetically derived live chimeric Horsepox Virus (rcHPXV) vaccine expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. vaccination well tolerated, as indicated by lack serious adverse events or significant changes clinical parameters. A single dose generated robust humoral responses African Green Monkeys Cynomolgus Macaques, measured total binding anti-SARS-CoV-2 S IgG neutralizing antibody titers against strain. In induced strong interferon-gamma (IFN-γ) mediated T cell response, promoting both pathogen clearance upper lower airways generation systemic response WA strain Future studies will assess newly emerging variants demonstrate its safety humans.

Language: Английский

Citations

1